Sunitinib-d 4

Overview

Sunitinib-d 4 is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC 50 s of 80 nM and 2 nM for VEGFR2 and PDGFRβ , respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > IRE1 | Products > Signaling Pathways > Mitophagy | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > PDGFR

Product Information

• Catalog No.: HY-10255AS1
• CAS No.: 1126721-79-6
• Molecular Formula: C22H23D4FN4O2
• Molecular Weight: 402.50
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source